Related Experiment Video

Updated: Jun 24, 2026

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

[Angiotensin (1-7) receptor]

Mitsuru Ohishi1, Hiromi Rakugi

  • 1Department of Geriatric Medicine, Graduate School of Medicine, Osaka University.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|April 8, 2009
PubMed

Insights

The Mas receptor, a protooncogene, acts as the functional receptor for angiotensin (1-7), revealing its role in cardiovascular and renal protection against hypertension.

Area of Science:

  • Molecular biology
  • Cardiovascular research
  • Nephrology

Background:

  • The Mas receptor, initially identified as a protooncogene, has a known role in cellular processes.
  • Angiotensin (1-7) is a biologically active peptide derived from angiotensin II.
  • Angiotensin converting enzyme 2 (ACE2) is crucial for producing angiotensin (1-7).

Purpose of the Study:

  • To identify the functional receptor for angiotensin (1-7).
  • To elucidate the molecular basis for angiotensin (1-7)'s physiological actions.
  • To explore the protective role of the angiotensin (1-7)/Mas receptor axis in hypertensive complications.

Main Methods:

  • In vivo detection of Mas protooncogene.
  • Biochemical assays to identify receptor-ligand interactions.
  • Comparative studies with angiotensin II and its type 1 receptor.

Main Results:

  • Mas was identified as the functional receptor for angiotensin (1-7).
  • This finding provides a molecular basis for angiotensin (1-7)'s actions.
  • Evidence suggests angiotensin (1-7)/Mas receptor signaling may counteract angiotensin II/type 1 receptor effects.

Conclusions:

  • The Mas receptor mediates the physiological effects of angiotensin (1-7).
  • This axis plays a potential protective role in hypertension-related renal and cardiovascular diseases.
  • The angiotensin (1-7)/Mas receptor pathway offers a target for managing hypertensive complications.

More Related Videos

Live Cell Imaging and 3D Analysis of Angiotensin Receptor Type 1a Trafficking in Transfected Human Embryonic Kidney Cells Using Confocal Microscopy09:51

Live Cell Imaging and 3D Analysis of Angiotensin Receptor Type 1a Trafficking in Transfected Human Embryonic Kidney Cells Using Confocal Microscopy

Published on: March 27, 2017

Single-channel Analysis and Calcium Imaging in the Podocytes of the Freshly Isolated Glomeruli12:19

Single-channel Analysis and Calcium Imaging in the Podocytes of the Freshly Isolated Glomeruli

Published on: June 27, 2015

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...